<DOC>
	<DOCNO>NCT02515175</DOCNO>
	<brief_summary>This study evaluate reduction viral shed vaccination new formulation GEN-003 subject genital HSV-2 infection . Two-thirds participant receive GEN-003 , one-third receive placebo .</brief_summary>
	<brief_title>Evaluating New Formulation Therapeutic HSV-2 Vaccine</brief_title>
	<detailed_description>This study randomize , double-blind , placebo-controlled clinical trial new formulation GEN-003 treatment HSV-2 genital infection . Eligible subject enter baseline period collect anogenital swab 28 consecutive day prior randomization . Each subject receive 3 dos 21 day interval complete second set anogenital swab 28 consecutive day third dose . Each subject follow one year third dose .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria A history least 3 9 report clinical occurrence prior 12 month , , currently suppressive antiviral therapy , history least 3 9 report clinical occurrence 12 month prior initiation antiviral suppressive therapy Diagnosis genital HSV2 infection &gt; 1 year Willing able provide write informed consent Willing perform comply study procedure include attend clinic visit schedule completion electronic lesion report form Willing use suppressive antiviral therapy 14 day prior start study duration study Men woman must willing practice highly effective method contraception may include , limited , abstinence , sex person sex , monogamous relationship vasectomize partner , vasectomy , tubal ligation , hysterectomy , license hormonal method , intrauterine device , barrier method ( e.g. , condom , diaphragm ) spermicide 28 day 90 day receive Study Drug Exclusion Criteria On suppressive antiviral therapy within 14 day start study Use topical steroid antiviral medication anogenital region within 14 day start study study Use tenofovir , lysine , medication supplement know purported affect HSV outbreak frequency intensity within 14 day start study History form ocular HSV infection , HSVrelated erythema multiforme , herpes meningitis encephalitis Immunocompromised individual Use corticosteroid within 30 day start study study immunosuppressive agent Presence history autoimmune disease regardless current treatment Current infection HIV hepatitis B C virus History hypersensitivity component vaccine Prior receipt GEN003 another vaccine contain HSV2 antigen Receipt investigational product within 30 day prior Dose 1 Receipt blood product within 90 day prior Dose 1 Planned use vaccine course study Pregnant nursing woman History drug alcohol abuse Other active , uncontrolled comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HSV</keyword>
	<keyword>Herpes</keyword>
	<keyword>Genital Herpes</keyword>
	<keyword>Vaccine</keyword>
</DOC>